Matthew Baker, Ph.D Email & Phone Number

Cambridge, GB

Paris, FR

ArgoBio Studio specializes in building therapeutics-focused companies by providing early-stage investment for translational research projects and supporting the corporate and strategic development of its portfolio companies. As Acting CEOs, we guide early-stage biotech startups through the investment process, helping them achieve key milestones to.

Belfast, Northern Ireland, GB

Cambridge, Cambridgeshire, GB

Cambridge, Cambridgeshire, GB

NeoPhore is creating novel small molecule immuno-oncology therapeutics by targeting the DNA mismatch repair (MMR) pathway. MMR deficiency is known to enhance immunotherapy induced immunity in solid tumors by engaging patients immune system through the generation of neoantigens. NeoPhore's small molecule MMR inhibitors will enable previously immunotherapy.

Oxford, Oxfordshire, GB

A synthetic biology company specializing in DNA design, protein expression optimization, antibody discovery and cell line development technologies and services. Acquired by WuXi Apptech in March 2021.

Co-founder of Denceptor Therapeutics (a joint venture between Baylor Institute for Immunology Research and Abzena) to develop antibody based dendritic cell targeted immunotherapies for cancer and autoimmune diseases.

Birmingham, GB

• Celentyx (based at The University of Birmingham UK) is focused on determining the mechanism of action, toxicity and efficacy of immune targeting drugs in oncology and autoimmune/inflammatory indications. Key aspects to.
• The company is leveraging its unique position in having access to disease relevant tissue from patients for use in efficacy, toxicity or MoA assays
• World class team of immunology and drug development experts with access to state of the art equipment
• The service division runs bespoke projects for companies that are developing immune targeting drugs (both small and large molecule candidates)
• Celentyx has an early stage pipeline of immunotherapeutic programs

San Diego, California, US

• KEY CONTRIBUTIONS
• Played key role as part of executive management team that raised £20 million in new shares after driving company’s IPO on the AIM with a pre-money valuation of £80 million.
• Successfully delivered contract service projects valued at up to £500,000.
• Brought diverse science teams together that generated successful outcomes through collaborative programs and synergistic projects.

• KEY CONTRIBUTIONS:
• Grew successful start-up company from a single employee to 45 employees.
• Maintained $5.9 million to $10 million in turnover every year, achieving 10%-20% growth throughout tenure.
• Increased number of antibody engineering deals 30% by implementing a new downstream technology development program to make manufacturing cell lines; provided integrated solution/platform to drive development of.
• Instumental in managing client projects including six molecules that are inclinical trials, Produced and applied novel antibody humanisation technology to 80+ therapeutic antibodies.
• Spearheaded design of 10+ protein therapeutics and cell lines that have entered clinical trials for clients.

• KEY CONTRIBUTIONS:
• Developed technology which resulted in several new patents and a platform technology that was provided as a service to the pharma/biotech industry for optimizing drug development.
• Spearheaded teams that developed four programs entering clinical trials, and established new technology IP for engineering protein therapeutics.

• KEY CONTRIBUTIONS:
• Provided advanced expertise in genomics and chemistry while successfully completing engineering projects.
• Managed a Research Assistant and collaborated with external consultants.
• Supervised tooling company suppliers in the production of novel columns used in DNA capture process.Achieved early career success as a Post-Doctoral Research Scientist at the Babraham Institute, Cambridge, UK. Co-wrote.